Fred Alger Management’s Trevi Therapeutics TRVI Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
– Sell
-66,490
Closed -$1.24M – 474
2026
Q2
$1.24M Buy
+66,490
New +$967K ﹤0.01% 352
2026
Q1
– Sell
-157,980
Closed -$1.98M – 513
2025
Q4
$1.98M Sell
157,980
-33,065
-17% -$382K 0.01% 315
2025
Q3
$1.75M Buy
191,045
+131,620
+221% +$987K 0.01% 330
2025
Q2
$325K Sell
59,425
-17,274
-23% -$107K ﹤0.01% 398
2025
Q1
$482K Buy
+76,699
New +$366K ﹤0.01% 366
2024
Q4
– Sell
-76,544
Closed -$256K – 474
2024
Q3
$256K Buy
+76,544
New +$228K ﹤0.01% 398

Other funds holding TRVI

Fred Alger Management's TRVI Position: Q3 2026 in Review

Fred Alger Management sold out of Trevi Therapeutics (TRVI) in Q3 2026, closing a stake of 66,490 shares — an estimated $1.24M sold.

Fred Alger Management first reported a position in TRVI in Q3 2024 and held it in 6 quarters. The position peaked at $1.98M in Q4 2025. 222 funds tracked by Wall St. Rank hold TRVI as of Q3 2026.

  • Fred Alger Management reported no remaining Trevi Therapeutics position as of Q3 2026 after selling out during the quarter.
  • Fred Alger Management sold 66,490 Trevi Therapeutics shares in Q3 2026, an estimated $1.24M.
  • Fred Alger Management first reported a position in Trevi Therapeutics in Q3 2024 and held it in 6 quarters.
  • Fred Alger Management's Trevi Therapeutics position peaked at $1.98M in Q4 2025.
  • 222 funds tracked by Wall St. Rank held Trevi Therapeutics as of Q3 2026.

Based on Fred Alger Management's 13F filing for Q3 2026, filed 16 Nov 2026.